Parallel Advisors
ARQT icon

Parallel Advisors’s Arcutis Biotherapeutics ARQT Stock Holding History

Parallel Advisors’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.77K Buy
67
+47
+235% +$1.23K ﹤0.01% 3668
2026
Q2 		$524 Sell
20
-27
-57% -$629 ﹤0.01% 3785
2026
Q1 		$1.11K Buy
47
+45
+2,250% +$1.15K ﹤0.01% 3522
2025
Q4 		$58 Buy
+2
New +$51 ﹤0.01% 3567
2025
Q2 		– Sell
-14
Closed -$219 – 3551
2025
Q1 		$219 Sell
14
-14
-50% -$197 ﹤0.01% 3368
2024
Q4 		$390 Buy
+28
New +$307 ﹤0.01% 3269
2023
Q3 		– Sell
-32
Closed -$305 – 3369
2023
Q2 		$305 Buy
+32
New +$355 ﹤0.01% 3192
2022
Q3 		– Sell
-7
Closed – – 3127
2022
Q2 		$0 Buy
+7
New +$144 ﹤0.01% 2978

Other funds holding ARQT

Candriam SCA
Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return
Perpetual Ltd
Perpetual Ltd Sydney, New South Wales, Australia $6.57B AUM 14.15% 1-Year Est. Return
Simplify Asset Management
Simplify Asset Management Las Vegas, Nevada $6.11B AUM 3.71% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return
Jay A. Fishman Ltd
Jay A. Fishman Ltd Troy, Michigan $1.24B AUM 21.21% 1-Year Est. Return
Privium Fund Management
Privium Fund Management Amsterdam, Netherlands $516M AUM 18.66% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Kornitzer Capital Management
Kornitzer Capital Management Shawnee Mission, Kansas $4.8B AUM 30.14% 1-Year Est. Return
Pavaki Capital Management
Pavaki Capital Management Pueblo, Colorado $294M AUM 34.46% 1-Year Est. Return
Essex Investment Management
Essex Investment Management Boston, Massachusetts $675M AUM 61.81% 1-Year Est. Return

Parallel Advisors's ARQT Position: Q3 2026 in Review

Parallel Advisors increased its Arcutis Biotherapeutics (ARQT) stake by 235% in Q3 2026, buying an estimated $1.23K and bringing the position to 67 shares worth $1.77K. The position accounts for ﹤0.01% of the portfolio, ranked #3668.

Parallel Advisors first reported a position in ARQT in Q2 2022 and has held it in 8 quarters since. 88 funds tracked by Wall St. Rank hold ARQT as of Q3 2026.

  • Parallel Advisors held 67 shares of Arcutis Biotherapeutics worth $1.77K as of Q3 2026.
  • Parallel Advisors bought 47 Arcutis Biotherapeutics shares in Q3 2026, an estimated $1.23K.
  • Arcutis Biotherapeutics made up ﹤0.01% of Parallel Advisors's portfolio in Q3 2026, its #3668 holding.
  • Parallel Advisors first reported a position in Arcutis Biotherapeutics in Q2 2022 and has held it in 8 quarters since.
  • 88 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q3 2026.

Based on Parallel Advisors's 13F filing for Q3 2026, filed 3 Nov 2026.